The PROTECT-V trial investigating UNIONs COVID-19 candidate receives Urgent Public Health Prioritization from the UK government
UNION therapeutics A/S (UNION) today announced that the National Institute for Health Research (NIHR) in the UK has granted Urgent Public Health (UPH) prioritization to the PROTECT-V trial – a platform study investigating UNION’s niclosamide-based treatment candidate for COVID-19 in kidney patients.
Clinical trials granted UPH prioritization by the NIHR are deemed critically important in the fight against COVID-19 and will thus receive infrastructure support allowing expedited recruitment for the study. NIHR is an entity under the Department of Health & Social Care of the UK government.
UPH prioritization will enable streamlined site set up across the UK, and facilitate rapid patient recruitment as a result of NIHR resource and clinical research network support being available.
The PROTECT-V trial is led by the Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge and involves researchers and patients from across the UK.
For more information visit: UNION Therapeutics
Published March 29 2021
Latest from CCTU
Team praised for “game-changing” heart trial
A senior Addenbrooke’s early phase trials researcher has praised patients, staff and sponsors who backed a landmark trial which could be a “game changer” in…
Improving outcomes for Crohn's patients
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.
Roll out of Cambridge-developed artificial pancreas is world first
An artificial pancreas developed with the help of staff and patients at Addenbrooke's Hospital is one of four new devices to be rolled out by…
